Liu Bao-yi, Zhao De-wei
Department of Orthopedics, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China.
Zhonghua Yi Xue Za Zhi. 2009 Oct 13;89(37):2629-33.
To understand the biological characteristics and osteogenic potential of hVEGF-165 gene modified marrow stromal stem cells and investigate the effect and value of treatment for osteonecrosis of femoral head by hVEGF-165 gene modified marrow stromal stem cells under arthroscope.
rAAV-2-hVEGF-165 plasmids were extracted and transfected into rabbit marrow stromal stem cells. hVEGF-165 mediated by adeno-associated virus (AAV) was used to transfect rMSCs. The transfection efficiency was detected with enhanced green fluorescent protein under fluorescence microscope. hVEGF-165 mediated by adeno-associated virus (AAV) was used to transfect rMSCs. Virus transfection stayed overnight after 90% cell converged. MOI was 105. The transcription and expression of hVEGF-165 protein expression were detected by RT-PCR and Western blot. The necrotic bone was emptied and then MSCs were implanted under arthroscope. The histology of femoral head was inspected at postoperative 2 - 8 weeks.
The expression of hVEGF-165 gene could be found distinctly in the transfected rabbit MSCs and hVEGF-165 protein in the supernatants of transfected cell cultures. The transfection efficiency of adeno-associated virus (AAV) transfected rMSCs was 70%. And rAAV-2-hVEGF-165 transfected rMSCs achieved an effective expression by RT-PCR and Western blot. hVEGF-165 could be found after a 48-hour transfection and peaked at Day 10. Immunohistochemical detection showed that the implanted rMSCs was positive at Week 2 and strong positive at Week 8. The compressive strength of the hVEGF-165 gene group approached that of normal control.
hVEGF-165 gene transfected rabbit MSCs can express hVEGF-165 with highly biological activity. It provides provided a basis for employing hVEGF-165 gene and MSCs based gene therapy for ONFH repairing and regeneration. rAAV-2-hVEGF-165/MSCs may be implanted accurately under arthroscope. Implantation of human BMP-2 gene transfected BMSCs can repair early-stage experimental femoral head necrosis.
了解人血管内皮生长因子165(hVEGF-165)基因修饰的骨髓基质干细胞的生物学特性和成骨潜能,探讨关节镜下hVEGF-165基因修饰的骨髓基质干细胞治疗股骨头坏死的效果及价值。
提取重组腺相关病毒2型-人血管内皮生长因子165(rAAV-2-hVEGF-165)质粒并转染兔骨髓基质干细胞。采用腺相关病毒(AAV)介导的hVEGF-165转染兔骨髓间充质干细胞(rMSCs)。在荧光显微镜下用增强型绿色荧光蛋白检测转染效率。采用腺相关病毒(AAV)介导的hVEGF-165转染rMSCs。细胞汇合率达90%后病毒转染过夜,感染复数(MOI)为105。通过逆转录-聚合酶链反应(RT-PCR)和蛋白质免疫印迹法(Western blot)检测hVEGF-165蛋白表达的转录和表达情况。关节镜下清除坏死骨后植入骨髓间充质干细胞。术后2至8周观察股骨头组织学情况。
在转染的兔骨髓间充质干细胞中可明显检测到hVEGF-165基因的表达,在转染细胞培养上清液中可检测到hVEGF-165蛋白。腺相关病毒(AAV)转染rMSCs的转染效率为70%。通过RT-PCR和Western blot检测,rAAV-2-hVEGF-165转染的rMSCs实现了有效表达。转染48小时后可检测到hVEGF-165,在第10天达到峰值。免疫组织化学检测显示,植入的rMSCs在第2周呈阳性,第8周呈强阳性。hVEGF-165基因组的抗压强度接近正常对照组。
hVEGF-165基因转染的兔骨髓间充质干细胞可表达具有高生物活性的hVEGF-165。这为采用hVEGF-165基因和基于骨髓间充质干细胞的基因治疗修复和再生股骨头坏死提供了依据。rAAV-2-hVEGF-165/骨髓间充质干细胞可在关节镜下准确植入。人骨形态发生蛋白2(BMP-2)基因转染的骨髓间充质干细胞植入可修复早期实验性股骨头坏死。